<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070381</url>
  </required_header>
  <id_info>
    <org_study_id>P-346-C-008</org_study_id>
    <nct_id>NCT01070381</nct_id>
  </id_info>
  <brief_title>Daily Disposable Toric Comparative Trial in Europe</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>CIBA VISION</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the subjective and objective performance of two
      daily disposable lenses for wearers with astigmatism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Comfort</measure>
    <time_frame>1 week of wear</time_frame>
    <description>Overall Comfort, as interpreted and reported by the participant on a questionnaire as a single, retrospective evaluation of 1-week's wear time. Overall comfort is measured on a 10-point scale, with 1 being poor and 10 being excellent.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Myopia</condition>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>nelfilcon A / ocufilcon D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nelfilcon A contact lenses worn first, with ocufilcon D contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ocufilcon D / nelfilcon A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ocufilcon D contact lenses worn first, with nelfilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nelfilcon A contact lens</intervention_name>
    <description>Commercially marketed, toric, soft contact lens for daily disposable wear</description>
    <arm_group_label>nelfilcon A / ocufilcon D</arm_group_label>
    <arm_group_label>ocufilcon D / nelfilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ocufilcon D contact lens</intervention_name>
    <description>Commercially marketed, toric, soft contact lens for daily disposable wear</description>
    <arm_group_label>nelfilcon A / ocufilcon D</arm_group_label>
    <arm_group_label>ocufilcon D / nelfilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current soft contact lens wearers able to be fit with soft toric lenses in the
             protocol-specified parameters.

          -  Achieve 0.5 or better distance visual acuity in each eye at time of dispense.

          -  Achieve acceptable or optimal fit in each eye at time of dispense.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Habitual daily disposable contact lens wearer.

          -  Sleeps in contact lenses overnight.

          -  Currently enrolled in an ophthalmic clinical trial.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <results_first_submitted>February 25, 2011</results_first_submitted>
  <results_first_submitted_qc>February 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2011</results_first_posted>
  <last_update_submitted>November 19, 2013</last_update_submitted>
  <last_update_submitted_qc>November 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Three participants were enrolled but not dispensed due to failing inclusion/exclusion criteria. These participants were included in the Actual Enrollment calculation, but not Participant Flow or Baseline Characteristics calculations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nelfilcon A / Ocufilcon D</title>
          <description>Nelfilcon A contact lenses worn first, with ocufilcon D contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.</description>
        </group>
        <group group_id="P2">
          <title>Ocufilcon D / Nelfilcon A</title>
          <description>Ocufilcon D contact lenses worn first, with nelfilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1, 1 Week of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109">One subject could not be dispensed into Period 1 product. Subject started Period 2 wear.</participants>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109">One subject could not continue into Period 2 due to product unavailability.</participants>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2, 1 Week of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Handling</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unacceptable Vision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>This reporting group includes all enrolled and dispensed subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="217"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Comfort</title>
        <description>Overall Comfort, as interpreted and reported by the participant on a questionnaire as a single, retrospective evaluation of 1-week's wear time. Overall comfort is measured on a 10-point scale, with 1 being poor and 10 being excellent.</description>
        <time_frame>1 week of wear</time_frame>
        <population>Analysis conducted per protocol, with exclusions due to reasons such as, major protocol deviations as determined by masked review; discontinuations; and/or missing responses.</population>
        <group_list>
          <group group_id="O1">
            <title>Nelfilcon A</title>
            <description>Commercially marketed, toric, soft contact lens for daily disposable wear</description>
          </group>
          <group group_id="O2">
            <title>Ocufilcon D</title>
            <description>Commercially marketed, toric, soft contact lens for daily disposable wear</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Comfort</title>
          <description>Overall Comfort, as interpreted and reported by the participant on a questionnaire as a single, retrospective evaluation of 1-week's wear time. Overall comfort is measured on a 10-point scale, with 1 being poor and 10 being excellent.</description>
          <population>Analysis conducted per protocol, with exclusions due to reasons such as, major protocol deviations as determined by masked review; discontinuations; and/or missing responses.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="1.9"/>
                    <measurement group_id="O2" value="7.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for the duration of the trial = 87 days. Individual exposure = 2 weeks (1 week per product)</time_frame>
      <desc>All enrolled and exposed participants. Common lens-related symptoms were collected at baseline. Any 3-grade change (1 or more symptoms) from baseline in frequency or severity was recorded as an adverse event. Frequency was collected on a 5-point scale, with 0=never and 4=always. Severity was collected on a 5-point scale, with 0=none and 4=severe.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nelfilcon A</title>
          <description>Commercially marketed, toric, soft contact lens for daily disposable wear</description>
        </group>
        <group group_id="E2">
          <title>Ocufilcon D</title>
          <description>Commercially marketed, toric, soft contact lens for daily disposable wear</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>3-grade change in symptoms (frequency and/or severity) from baseline</sub_title>
                <description>As collected on a questionnaire. Symptoms included 1 or more of the following: lens awareness, discomfort, blurred vision.</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="217"/>
                <counts group_id="E2" events="35" subjects_affected="27" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Priya Janakiraman, OD, FAAO / Head, Global Clinical Affairs</name_or_title>
      <organization>CIBA VISION</organization>
      <phone>1-800-241-7629</phone>
      <email>priya.janakiraman@cibavision.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

